Oslo, Norway, October 4, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, announced today that its Chief Executive Officer, Michael
Engsig and Chief Innovation and Strategy Officer, Agnete Fredriksen, will
participate in a fireside chat at Guggenheim Securities' 2nd Annual Vaccine and
Infectious Disease Days on October 6, 2021 at 3.30 pm EDT / 9.30 pm CEST.

A link to the live fireside chat may be found here:
https://kvgo.com/guggenheim/vaccibody-oct-2021


About Vaccibody 
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Vaccibody's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and elicit efficacious clinical responses. Its lead product candidates include
VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to
Genentech and is in Phase 1b for the treatment of locally advanced and
metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and
neck, renal-, and bladder cancer